A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 16
- Registration Number
- NCT01313143
- Locations
- 🇨🇿
AOP contract research facility, Pilsen, Czech Republic
Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 146
- Registration Number
- NCT01230775
- Locations
- 🇦🇹
Universitätsklinik für Innere Medizin III, Universitätsklinikum Salzburg, Salzburg, Austria
🇧🇬University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski", Pleven, Bulgaria
🇷🇴University Emergency Hospital, Bucharest, Romania
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 24
- Registration Number
- NCT01193699
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Registration Number
- NCT01065038
- Locations
- 🇩🇪
Center Munich, Munich, Bavaria, Germany
🇨🇿Center Olomouc, Olomouc, Czech Republic
🇵🇱Center Gdansk, Gdansk, Poland
Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2009-08-27
- Lead Sponsor
- AOP Orphan Pharmaceuticals AG
- Target Recruit Count
- 160
- Registration Number
- NCT00671736
- Locations
- 🇦🇹
Medical University, Graz, Austria
© Copyright 2024. All Rights Reserved by MedPath